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Effect of sodium bicarbonate (12 mmoi/i. at arrow) on 
cytoplasmic pH (pH,) in bovine aortic endothelial cells 
(AG4762. Nationallnstituteof Aging cell repository. passage 
11) loaded with BCECF. trypsinised and suspended in stirred 
H EPES buffered Tyrode's solution at room temperature. 
surface of the cell membrane. Despite this, we have observed 
qualitatively similar responses in suspensions of bovine aortic 
endothelial cells (figure), so the effect is not peculiar to platelets. Dr 
lies and Dr Beech have very interesting data demonstrating 
increased pH in liver caus~ by a 15 min intravenous infusion of 
molar sodi~ bicarbonate _ in the ketoacidotic rat. It will be 
particularly interesting when the resolving power of this method is 
increased to permit measurement of the effect of bicarbonate on pH, 
in cardiac muscle in animal models of cardiac arrest. 
Professor Cohen and Professor Woods in their 1987 chapter' on 
treatment of acid-base disturbances presented a balanced account of 
the arguments, and we are sorry that they feel that our statement 
that they advocated the use of bicarbonate misrepresented them. 
They did write that hypertonic bicarbonate is standard therapy for 
the acidosis of cardiac arrest, but also pointed out that such therapy 
is not of unequivocal benefit. There are several precedents of 
treatments once used routinely in severely ill patients on grounds 
that they appeared reasonable but which have subsequently been 
proved to be positively hannful. Although our studies showing 
reduction in pH, in response to bicarbonate in vitro are not 
conclusive evidence that such a deleterious effect occurs during 
bicarbonate therapy, we feel that the fmdings shift the burden of 
proof towards those that favour such treatment: perhaps the time is 
right to plan controlled trials of bicarbonate therapy despite the 
formidable difficulties that Cohen and Woods rightly identify. 
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Factor VIII:C inhibitor associated with 
monoclonal-anti body-purified FVIII 
concentrate 
SIR,-Several comments need to be made to put in perspective the 
letter by Dr Kessler and Dr Sachse Gune 9, p 1403) concerning 
factor VIII:C inhibitor formation. 
The actual rate of inhibitor formation in patients with severe 
haemophilia A, followed from childhood to adulthood, is unknown. 
The estimated rates of 5-15% are derived from cross-sectional 
rather than longitudinal studies and include patients with all degrees 
of severity. In one large "natural history" study, 29% of patients 
had inhibitor after 30 years of age, and at a time when only crude 
preparations of factor VIII:C were available.' Most inhibitors 
developed in children. It has been estimated that if severely affected 
(factorVIII:C < I %) children were followed for 20 or 30 years then 
an inhibitor might develop in 30% or more (L. Aledon, personal 
communication). The cited rate of inhibitor formation in previously 
unexposed patients (7 of 39 or 18%) is not extraordinary or 
unexpected.' 
The Malmo procedure for induction of immune tolerance has 
been successfully applied to many patients, but the actual response 
rate of patients is upknown.3 Of the 11 patients treated by Nilsson et 
al, 2 (18%) did not respond. There is no way to know the 
significance of "the failure of the immune tolerance induction" in 
Kessler and Sachse's patient. The speculation that the manufacture 
of monoclonal-antibody-derived factor VIII:C could be associated 
with subtle denaturation of a native factor VIII:C protein, and 
creation of a neoantigen, is without factual suppon. The article 
referenced, with respect to alterations in the factor VIII:C gene, 
actually provides data that argue against this mechanism. Extensive 
animal testing during the preclinical laboratory evaluation of 
'Monoclate' failed to reveal any evidence of neoantigen formation! 
It is premature to suggest that use of ultra-pure factor VIII:C 
produCts is related to an increased rate of inhibitor development, or 
to speculate on their failure to suppress inhibitors. 
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Prevention of spontaneous diabetes in BB 
rats with FK 506 
SIR,-Cyclosporin can mitigate or prevent autoimmune BB rat 
diabetes, ,-3 and can induce remissions of human type I diabetes if 
instituted early after diagnosis and in adequate doses.4-6 The potent 
new immunosuppressive agent, FK 506, which has had extensive 
clinical trials in transplantation,' suppresses T -cell activation in the 
same general way as cyclosporin does, by inhibiting the 
transcription of mRNA for early phase Iymphokines such as 
interleukin-2, interleukin-3, and y-interferon." We have examined 
the influence of daily enteral tap water_ (group 1, n = 20), 1 mgfkg 
FK 506 (group 2, n = 19), or 2 mg/kg FK 506 (group 3, n = 20) on 
the incidence of spontaneous diabetes in our BB rat colony. The 59 
animals were obtained from seven consecutive litters, randomly 
deployed to the three sex-matched groups, raised under controlled 
lighting, and allowed tap water and regular rat food (Purina 'Chow 
5001') ad libitum. Treatment was between 30 and 120 days of age. 
The FK 506 (Fujisawa Pharmaceutical, Osaka) was dispersed with 
hydroxypropylmethylce11ulose, diluted in tap water by sonication, 
and administered by gastric intubation. Onset of diabetes was 
diagnosed by glycosuria (tested thrice weekly) and confirmed by 
non-fasted blood sugar above 200 mg/dl from tail vein samples for 3 
consecutive days. 
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Onset and incidence of diabetes during FK 506 treatment. 
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FATE AFTER 120 DAYS OF RATS TREATED WITH FK 506 
FROM DAYS',,30T0120 
Group 1 Group 2 Group 3 
Outcome (water) (1'0 mg/kg) (2'0 mg/kg) 
Survival ? 120 days without 
diabetes 5/20 16/19 20/20 
Killed at 120 days 20f5 60f16 6 of20 
Animals remaining beyond 120 
days 3 10 14 
Survival ? 150 days without 
diabetes 3 8* 14 
Killed at 150 days 30f3 20f8 20f14 
Animals remaining beyond 150 
days .. 6 12 
Survival 165-195 days without 
diabetes .. 6 9t 
·Other 2 animals became diabetic. at 132 and 147 days. 
tOther 3 animals used for breeding and became diabetic while pregnant at 170. 175. 
and 180 days. 
During the 90-day treatment period, diabetes developed in 15,3, 
and none of the tap water, low-dose FK 506, and high-dose FK 506 
groups, respectively (figure). Rats with diabetes died within a few 
days but there was no mortality or inhibition of weight gain among 
the non-diabetic rats. In these protected animals, blood glucose 
levels, measured every 2 weeks, and hepatic and renal function tests 
were always normal. 
9 FK 506-treated rats (3 from group 2, 6 from group 3) had 
intraperitoneal glucose tolerance tests (2 g/kg) on the last day of 
treatment, and pancreas insulin content was measured by 
radioimmunoassay in 11 of the group 2 and 3 non-diabetic animals 
which were killed. The results were normal, and not different from 
those in 6 untreated Wistar-Furth (non-BB) rats. On 
histopathological examination, the pancreases of the non-diabetic 
FK 506-treated rats had little or no evidence of the insulitis and 
periducru1ar mononuclear inflammation which was characreristic of 
the non-treated diabetic animals. 
As with ciclosporin3 the protective effecr of FK 506 'often 
outlasted the time of active treatment (table). Glucose intolerance, 
which has been described in BB rats under cyclosporin treatment: 
was not observed with the doses ofFK 506 used in this study. These 
findings support the possibility of clinical trials of immune 
intervention for recent onset diabetes. 
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Amaurosis fugax and antiphospholipid 
antibodies 
SlR,-Dr Booy (June 23, p 1538) describes a case of amaurosis 
fugax in a young woman and discusses whether a carotid angiogram 
should be done. The far less invasive procedure of phospholipid 
(aPL) antibody detection may be appropriate. The 
antiphospholipid antibody syndrome (APS), whose clinical features 
include thrombosis, thrombocytopenia, and recurrent 
miscarriages,' affects mainly young women. The solid phase 
cardiolipin antibody test and the lupus anticoagulant test are 
regarded as useful diagnostic tools.2 Although a close pathogenetic 
link between autoantibodies and neurological diseases is still 
speculative, the clinical association of phospholipid antibodies and 
neurological disorders is no longer in dispute. Primary APS 
(without signs of definite connective-tissue disease) has been 
reported in association with focal cerebral ischaemia, migraine, 
transient global amnesia, chorea, myelopathy, and ocular 
ischaemia.3,4 These antibodies have been described in systemic 
lupus erythematosus (SLE) in children, the highest levels occurring 
during neurological events,' and in children without any underlying 
pathological condition (primary APS).6 
During the past two years we have studied fifteen female patients 
with primary APS. Amaurosis fugax is the only symptom in one 
patient; another patient presents with amaurosis fugax during 
recurrent episodes of migraine; a third has a central retinal artery 
thrombosis with permanent visual impairment. Asherson et al7 
pointed out that cardiolipin antibodies represent a risk factor for 
occlusive ocular vascular disease in SLE. Several of our SLE 
patients with cardiolipin antibodies have migraine with or without 
visual disturbances. We agree with Booy that carotid angiography is 
not indicated in young patients with amaurosis fugax, but we 
suggest that phospholipid antibodies be looked for. 
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Acute viral hepatitis B in children: lack of 
chronicity 
SIR,-Chronic hepatitis B virus infection had been shown to evolve 
from acute viral hepatitis B (AVHB) in 5-10% of cases.' However, 
recent studies in adults have shown that chronic infection develops 
after AVHB in only 1-3% of patiems., .. 1 To evaluate the rate of 
progression to chronic infection after A VHB in children ofless than 
15 years old we followed prospectively 154 patients classified as 
having A VHB on hospital admission. All the children were pOSitive 
for hepatitis B surface antigen (HBsAg) and/or IgM anti-HBs on 
admission, and were followed for between 3 and 24 months after 
admission. Diagnosis of acute viral hepatItis was made from clinical, 
biochemical, and serological features. Enzyme immunoassay (ElA) 
was used to detect HBsAg (Abbott) and anti-HBV antibodies 
(Institute of Organic Synthesis, Riga, USSR; Behring), anti-
hepatitis A virus (HAV'! antibody (Abbott), and anti-hepatitis D 
